$2.6T
Total marketcap
$169.2B
Total volume
BTC 49.99%     ETH 15.81%
Dominance

argenx SE ARGX Stock

361.54 USD {{ price }} -2.623354% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
22.12B USD
LOW - HIGH [24H]
361.44 - 368.44 USD
VOLUME [24H]
327.06K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-4.12 USD

argenx SE Price Chart

argenx SE ARGX Financial and Trading Overview

argenx SE stock price 361.54 USD
Previous Close 392.52 USD
Open 392.65 USD
Bid 0 USD x 1100
Ask 0 USD x 1300
Day's Range 390.8 - 397.83 USD
52 Week Range 333.06 - 423.99 USD
Volume 125.4K USD
Avg. Volume 213.24K USD
Market Cap 22.05B USD
Beta (5Y Monthly) 0.468582
PE Ratio (TTM) N/A
EPS (TTM) -4.12 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 471.79 USD

ARGX Valuation Measures

Enterprise Value 548.01B USD
Trailing P/E N/A
Forward P/E -104.769844
PEG Ratio (5 yr expected) -1.75
Price/Sales (ttm) 34.48517
Price/Book (mrq) 194.92352
Enterprise Value/Revenue 857.054
Enterprise Value/EBITDA -1143.389

Trading Information

argenx SE Stock Price History

Beta (5Y Monthly) 0.468582
52-Week Change 13.16%
S&P500 52-Week Change 20.43%
52 Week High 423.99 USD
52 Week Low 333.06 USD
50-Day Moving Average 394.71 USD
200-Day Moving Average 377.48 USD

ARGX Share Statistics

Avg. Volume (3 month) 213.24K USD
Avg. Daily Volume (10-Days) 120.81K USD
Shares Outstanding 55.68M
Float 1.38B
Short Ratio 4.15
% Held by Insiders 0.0020%
% Held by Institutions 54.86%
Shares Short 1.12M
Short % of Float N/A
Short % of Shares Outstanding 2.00%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -79.96%
Operating Margin (ttm) -94.56%
Gross Margin -13.17%
EBITDA Margin -74.95%

Management Effectiveness

Return on Assets (ttm) N/A
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 639.41M USD
Revenue Per Share (ttm) 0.46 USD
Quarterly Revenue Growth (yoy) 630.19%
Gross Profit (ttm) -251786000 USD
EBITDA -479285760 USD
Net Income Avi to Common (ttm) -511279008 USD
Diluted EPS (ttm) -9.2
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.19B USD
Total Cash Per Share (mrq) 1.58 USD
Total Debt (mrq) 12.43M USD
Total Debt/Equity (mrq) 0.44 USD
Current Ratio (mrq) N/A
Book Value Per Share (mrq) 2.03172

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) N/A

Profile of argenx SE

Country United States
State N/A
City Amsterdam
Address Laarderhoogtweg 25
ZIP 1101EB
Phone 31 10 703 8441
Website https://www.argenx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 843

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Q&A For argenx SE Stock

What is a current ARGX stock price?

argenx SE ARGX stock price today per share is 361.54 USD.

How to purchase argenx SE stock?

You can buy ARGX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for argenx SE?

The stock symbol or ticker of argenx SE is ARGX.

Which industry does the argenx SE company belong to?

The argenx SE industry is Biotechnology.

How many shares does argenx SE have in circulation?

The max supply of argenx SE shares is 61.17M.

What is argenx SE Price to Earnings Ratio (PE Ratio)?

argenx SE PE Ratio is now.

What was argenx SE earnings per share over the trailing 12 months (TTM)?

argenx SE EPS is -4.12 USD over the trailing 12 months.

Which sector does the argenx SE company belong to?

The argenx SE sector is Healthcare.

argenx SE ARGX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
Nasdaq Next Generation 100 Inde NGX 1138.09 USD
-0.13
1137.73 USD 1146.36 USD